Genmab A/S Stock

Genmab A/S Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Genmab A/S (GMAB.CO) as of Aug 14, 2026 is 123.16 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 99.07 % — a change of 24.31% (higher).

Cash Conversion

123.16 %

YoY

24.31%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Genmab A/S is 2026 123.16 % . Cash Conversion Rate (OCF/Net Income) of Genmab A/S was 2025 99.07 % . It decreases by 24.31% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Cash Conversion Rate (OCF/Net Income) of Genmab A/S is 123.16 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Genmab A/S changed from 99.07 % to 123.16 %, representing a 24.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Genmab A/S

All Key Metrics — Genmab A/S